| 1 |
Fiorino G，Bonifacio C，Allocca M，et al.Impact of therapies on bowel damage in Crohn′s disease[J].United European Gastroenterol J，2020，8(4)：410-417.
|
| 2 |
Peyrin-Biroulet L，Loftus EV，Jr Colombel JF，et al.Early Crohn disease：a proposed definition for use in disease-modification trials[J].Gut，2010，59(2)：141-147.
|
| 3 |
Im JP，Ye BD，Kim YS，et al.Changing treatment paradigms for the management of inflammatory bowel disease[J].Korean J Intern Med，2018，33(1)：28-35.
|
| 4 |
Le Berre C，Peyrin-Biroulet L，group Spirit-Ioibd study.Selecting End Points for Disease-Modification Trials in Inflammatory Bowel Disease：the SPIRIT Consensus From the IOIBD[J].Gastroenterology，2021，160(5)：1452-1460 e1421.
|
| 5 |
Berg DR，Colombel JF，Ungaro R．The Role of Early Biologic Therapy in Inflammatory Bowel Disease[J].Inflamm Bowel Dis，2019，25(12)：1896-1905.
|
| 6 |
龚剑峰，朱维铭．克罗恩病治疗的新模式——降阶梯治疗[J].肠外与肠内营养，2009，16(6)：377-380.
|
| 7 |
王蓉，唐源．生物制剂在炎症性肠病治疗中的应用分析[J].现代消化及介入诊疗，2021，26(8)：1068-1071，1074.
|
| 8 |
Ruemmele FM，Veres G，Kolho KL，et al.European Crohn′s，Colitis Organisation，European Society of Pediatric Gastroenterology Hepatology，Nutrition.Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn′s disease[J].J Crohns Colitis，2014，8(10)：1179-1207.
|
| 9 |
李玥，钱家鸣．抗肿瘤坏死因子α单克隆抗体治疗炎症性肠病专家共识(2017)[J].协和医学杂志，2017，8(Z2)：239-243.
|
| 10 |
Lichtenstein GR，Loftus EV，Isaacs KL，et al.ACG Clinical Guideline：Management of Crohn′s Disease in Adults[J].Am J Gastroenterol，2018，113(4)：481-517.
|
| 11 |
中华医学会消化病学分会炎症性肠病学组．炎症性肠病诊断与治疗的共识意见(2018年，北京)[J].中华消化杂志，2018，38(5)：292-311.
|
| 12 |
Feuerstein JD，Isaacs KL，Schneider Y，et al.Institute Clinical Guidelines.AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis[J].Gastroenterology，2020，158(5)：1450-1461.
|
| 13 |
D′Haens G，Baert F，van Assche G，et al.Belgian Inflammatory Bowel Disease Research Group，North-Holland Gut Club.Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn′s disease：an open randomised trial[J].Lancet，2008，371(9613)：660-667.
|
| 14 |
Schreiber S，Reinisch W，Colombel JF，et al.Subgroup analysis of the placebo-controlled CHARM trial：increased remission rates through 3 years for adalimumab-treated patients with early Crohn′s disease[J].J Crohns Colitis，2013，7(3)：213-221.
|
| 15 |
Amezaga AJ，Van Assche G．Practical Approaches to "Top-Down" Therapies for Crohn′s Disease[J].Curr Gastroenterol Rep，2016，18(7)：35.
|
| 16 |
Kim MJ，Kim E，Kang B，et al.Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis：A Step-Up versus a Top-Down Strategy[J].Yonsei Med J，2021，62(7)：608-614.
|
| 17 |
Baumgart DC，Sandborn WJ.Crohn′s disease[J].Lancet，2012，380(9853)：1590-1605.
|
| 18 |
Danese S，Fiocchi C．Ulcerative colitis[J].N Engl J Med，2011，365(18)：1713-1725.
|
| 19 |
Rutgeerts P，Vermeire S，Van Assche G．Biological therapies for inflammatory bowel diseases[J].Gastroenterology，2009，136(4)：1182-1197.
|
| 20 |
Yamamoto-Furusho JK.Innovative therapeutics for inflammatory bowel disease[J].World J Gastroenterol，2007，13(13)：1893-1896.
|
| 21 |
Danese S．Mechanisms of action of infliximab in inflammatory bowel disease：an anti-inflammatory multitasker[J].Dig Liver Dis，2008，40 Suppl 2：S225-228.
|
| 22 |
中国医药教育协会炎症性肠病专业委员会．中国炎症性肠病生物制剂治疗专家建议(试行)[J/OL].中华消化病与影像杂志(电子版)，2021，11(6)：244-256.
|
| 23 |
Rutgeerts P，Van Assche G，Sandborn WJ，et al.Adalimumab induces and maintains mucosal healing in patients with Crohn′s disease：data from the EXTEND trial[J].Gastroenterology，2012，142(5)：1102-1111 e1102.
|
| 24 |
Panaccione R，Colombel JF，Sandborn WJ，et al.Adalimumab maintains remission of Crohn′s disease after up to 4 years of treatment：data from CHARM and ADHERE[J].Aliment Pharmacol Ther，2013，38(10)：1236-1247.
|
| 25 |
Loftus EV，Reinisch W，Panaccione R，et al.Adalimumab Effectiveness Up to Six Years in Adalimumab-naive Patients with Crohn′s Disease：Results of the PYRAMID Registry[J].Inflamm Bowel Dis，2019，25(9)：1522-1531.
|
| 26 |
Colombel JF，Sandborn WJ，Ghosh S，et al.Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis：Data from ULTRA 1，2，and 3[J].Am J Gastroenterol，2014，109(11)：1771-1780.
|
| 27 |
Cholapranee A，Hazlewood GS，Kaplan GG，et al.Systematic review with meta-analysis：comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn′s disease and ulcerative colitis controlled trials[J].Aliment Pharmacol Ther，2017，45(10)：1291-1302.
|
| 28 |
Rutgeerts P，Diamond RH，Bala M，et al.Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn′s disease[J].Gastrointest Endosc，2006，63(3)：433-442；quiz 464.
|
| 29 |
Havrdova E，Hutchinson M，Kurukulasuriya NC，et al.Oral BG-12(dimethyl fumarate)for relapsing-remitting multiple sclerosis：a review of DEFINE and CONFIRM.Evaluation of：Gold R，Kappos L，Arnold D，et al.Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis.N Engl J Med 2012；367：1098-107；and Fox RJ，Miller DH，Phillips JT，et al.Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.N Engl J Med 2012；367：1087-97[J].Expert Opin Pharmacother，2013，14(15)：2145-2156.
|
| 30 |
Torres J，Bonovas S，Doherty G，et al.ECCO Guidelines on Therapeutics in Crohn′s Disease：Medical Treatment[J].J Crohns Colitis，2020，14(1)：4-22.
|
| 31 |
Ran Z，Wu K，Matsuoka K，et al.Asian Organization for Crohn′s and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia[J].J Gastroenterol Hepatol，2021，36(3)：637-645.
|
| 32 |
Lamb CA，Kennedy NA，Raine T，et al.IBD guidelines eDelphi consensus group.Gaya DR，Iqbal TH，Taylor SA，et al.British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults[J].Gut，2019，68(Suppl 3)：s1-s106.
|
| 33 |
Rubin DT，Ananthakrishnan AN，Siegel CA，et al.ACG Clinical Guideline：Ulcerative Colitis in Adults[J].Am J Gastroenterol，2019，114(3)：384-413.
|
| 34 |
Amiot A，Bouguen G，Bonnaud G，et al.French National Consensus Clinical guidelines for the management of I．B.D.study group.Clinical guidelines for the management of inflammatory bowel disease：Update of a French national consensus[J].Dig Liver Dis，2021，53(1)：35-43.
|
| 35 |
Matsuoka K，Kobayashi T，Ueno F，et al.Evidence-based clinical practice guidelines for inflammatory bowel disease[J].J Gastroenterol，2018，53(3)：305-353.
|
| 36 |
Present DH，Rutgeerts P，Targan S，et al.Infliximab for the treatment of fistulas in patients with Crohn′s disease[J].N Engl J Med，1999，340(18)：1398-1405.
|
| 37 |
Rutgeerts P，Sandborn WJ，Feagan BG，et al.Infliximab for induction and maintenance therapy for ulcerative colitis[J].N Engl J Med，2005，353(23)：2462-2476.
|
| 38 |
Reinisch W，Sandborn WJ，Hommes DW，et al.Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis：results of a randomised controlled trial[J].Gut，2011，60(6)：780-787.
|
| 39 |
Sands BE，Blank MA，Patel K，et al.Study Accent Ii.Long-term treatment of rectovaginal fistulas in Crohn′s disease：response to infliximab in the ACCENT Ⅱ Study[J].Clin Gastroenterol Hepatol，2004，2(10)：912-920.
|
| 40 |
Colombel JF，Sandborn WJ，Reinisch W，et al.Group Sonic Study.Infliximab，azathioprine，or combination therapy for Crohn′s disease[J].N Engl J Med，2010，362(15)：1383-1395.
|
| 41 |
Sandborn WJ，Feagan BG，Rutgeerts P，et al.Group Gemini Study.Vedolizumab as induction and maintenance therapy for Crohn′s disease[J].N Engl J Med，2013，369(8)：711-721.
|
| 42 |
Feagan BG，Sandborn WJ，Gasink C，et al.Group Uniti-Im-Uniti Study.Ustekinumab as Induction and Maintenance Therapy for Crohn′s Disease[J].N Engl J Med，2016，375(20)：1946-1960.
|
| 43 |
Gisbert JP，Chaparro M．Ustekinumab to treat Crohn′s disease[J].Gastroenterol Hepatol，2017，40(10)：688-698.
|
| 44 |
Chang S，Hudesman D．First-Line Biologics or Small Molecules in Inflammatory Bowel Disease：a Practical Guide for the Clinician[J].Curr Gastroenterol Rep，2020，22(2)：7.
|
| 45 |
Feagan BG，Rutgeerts P，Sands BE，et al.Group Gemini Study.Vedolizumab as induction and maintenance therapy for ulcerative colitis[J].N Engl J Med，2013，369(8)：699-710.
|
| 46 |
Mosli MH，MacDonald JK，Bickston SJ，et al.Vedolizumab for induction and maintenance of remission in ulcerative colitis：a Cochrane systematic review and meta-analysis[J].Inflamm Bowel Dis，2015，21(5)：1151-1159.
|
| 47 |
Jarnerot G，Hertervig E，Friis-Liby I，et al.Infliximab as rescue therapy in severe to moderately severe ulcerative colitis：a randomized，placebo-controlled study[J].Gastroenterology，2005，128(7)：1805-1811.
|
| 48 |
Sandborn WJ，Su C，Sands BE，et al.Octave Induction Octave Induction，Investigators Octave Sustain.Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis[J].N Engl J Med，2017，376(18)：1723-1736.
|
| 49 |
Bressler B，Marshall JK，Bernstein CN，et al.Toronto Ulcerative Colitis Consensus Group.Clinical practice guidelines for the medical management of nonhospitalized ulcerative colitis：the Toronto consensus[J].Gastroenterology，2015，148(5)：1035-1058 e1033.
|
| 50 |
Roblin X，Marotte H，Rinaudo M，et al.Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases[J].Clin Gastroenterol Hepatol，2014，12(1)：80-84 e82.
|
| 51 |
Afif W，Loftus EV，Jr Faubion WA，et al.Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease[J].Am J Gastroenterol，2010，105(5)：1133-1139.
|
| 52 |
Roblin X，Rinaudo M，Del Tedesco E，et al.Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases[J].Am J Gastroenterol，2014，109(8)：1250-1256.
|
| 53 |
Hanauer SB，Feagan BG，Lichtenstein GR，et al.Group Accent I．Study.Maintenance infliximab for Crohn′s disease：the ACCENT I randomised trial[J].Lancet，2002，359(9317)：1541-1549.
|
| 54 |
Hanauer SB，Sandborn WJ，Rutgeerts P，et al.Human anti-tumor necrosis factor monoclonal antibody(adalimumab)in Crohn′s disease：the CLASSIC-I trial[J].Gastroenterology，2006，130(2)：323-333；quiz 591.
|
| 55 |
Colombel JF，Sandborn WJ，Rutgeerts P，et al.Adalimumab for maintenance of clinical response and remission in patients with Crohn′s disease：the CHARM trial[J].Gastroenterology，2007，132(1)：52-65.
|
| 56 |
Sandborn WJ，Hanauer SB，Rutgeerts P，et al.Adalimumab for maintenance treatment of Crohn′s disease：results of the CLASSIC Ⅱ trial[J].Gut，2007，56(9)：1232-1239.
|
| 57 |
Sandborn WJ，Feagan BG，Stoinov S，et al.Investigators Precise Study.Certolizumab pegol for the treatment of Crohn′s disease[J].N Engl J Med，2007，357(3)：228-238.
|
| 58 |
Schreiber S，Khaliq-Kareemi M，Lawrance IC，et al.Investigators Precise Study.Maintenance therapy with certolizumab pegol for Crohn′s disease[J].N Engl J Med，2007，357(3)：239-250.
|
| 59 |
Sandborn WJ，Feagan BG，Marano C，et al.Group Pursuit-Sc Study.Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis[J].Gastroenterology，2014，146(1)：85-95；quiz e14-85.
|
| 60 |
Sandborn WJ，Feagan BG，Marano C，et al.URSUIT-Maintenance Study Group.Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis[J].Gastroenterology，2014，146(1)：96-109 e101.
|
| 61 |
Burri E，Juillerat P，Maillard MH，et al.Position statement on the use of biosimilars in inflammatory bowel disease[J].Swiss Med Wkly，2019，149：w20148.
|
| 62 |
Su J，Li M，He L，Zhao D，et al.Comparison of the Efficacy and Safety of Adalimumab(Humira)and the Adalimumab Biosimilar Candidate(HS016)in Chinese Patients with Active Ankylosing Spondylitis：A Multicenter，Randomized，Double-Blind，Parallel，Phase Ⅲ Clinical Trial[J].BioDrugs，2020，34(3)：381-393.
|
| 63 |
Jiang XL，Cui HF，Gao J，et al.Low-dose Infliximab for Induction and Maintenance Treatment in Chinese Patients With Moderate to Severe Active Ulcerative Colitis[J].J Clin Gastroenterol, 2015，49(7)：582-588.
|
| 64 |
Zhang ZM，Li W，Jiang XL.Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis：A Meta-Analysis of Published Placebo-Controlled Trials[J].Gut Liver，2016，10：262-274.
|
| 65 |
江学良．中国中西医结合学会消化系统疾病专业委员会炎症性肠病专家委员会．中国中西医结合炎症性肠病质量控制指标共识[J/OL].中华消化病与影像杂志(电子版)，2021，11(4)：149-151.
|